1. Effectiveness of monovalent rotavirus vaccine against hospitalizations due to all rotavirus and equine-like G3P[8] genotypes in Haiti 2014-2019
- Author
-
Stanley Juin, Jacqueline E. Tate, Roopal Patel, Jacques Boncy, Mark A. Katz, Yoran Grant-Greene, Gladzdin Jean-Denis, Mireille Kalou, David L. Fitter, Mathew D. Esona, Gerard A. Joseph, Negar Aliabadi, Eyal Leshem, Manise Pierre, Jocelyn Andre-Alboth, Michael D. Bowen, Anne Marie Desormeaux, Umesh D. Parashar, Eleanor Burnett, Melissa D. Etheart, and Patrick Dely
- Subjects
Rotavirus ,medicine.medical_specialty ,Genotype ,030231 tropical medicine ,Logistic regression ,medicine.disease_cause ,Vaccines, Attenuated ,Rotavirus Infections ,Article ,03 medical and health sciences ,Feces ,0302 clinical medicine ,Internal medicine ,Medicine ,Animals ,Humans ,030212 general & internal medicine ,Horses ,Child ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Public Health, Environmental and Occupational Health ,Rotavirus Vaccines ,virus diseases ,Infant ,Odds ratio ,Acute gastroenteritis ,Rotavirus vaccine ,Haiti ,Vaccination ,Hospitalization ,Infectious Diseases ,Child, Preschool ,Molecular Medicine ,Watery diarrhea ,business - Abstract
Background Rotavirus vaccines are effective in preventing severe rotavirus. Haiti introduced 2-dose monovalent (G1P[8]) rotavirus vaccine recommended for infants at 6 and 10 weeks of age in 2014. We calculated the effectiveness of rotavirus vaccine against hospitalization for acute gastroenteritis in Haiti. Methods We enrolled children 6–59 months old admitted May 2014-September 2019 for acute watery diarrhea at any sentinel surveillance hospital. Stool was tested for rotavirus using enzyme immunoassay (EIA) and genotyped with multiplex one-step RT-PCR assay and Sanger sequencing for stratification by genotype. We used a case-negative design where cases were children positive for rotavirus and controls were negative for rotavirus. Only children eligible for vaccination were included and a child was considered vaccinated if vaccine was given ≥ 14 days before enrollment. We used unconditional logistic regression to calculate odds ratios and calculated 2-dose and 1-dose vaccine effectiveness (VE) as (1 - odds ratio) * 100. Results We included 129 (19%) positive cases and 543 (81%) negative controls. Among cases, 77 (60%) were positive for equine-like G3P[8]. Two doses of rotavirus vaccine were 66% (95% CI: 44, 80) effective against hospitalizations due to any strain of rotavirus and 64% (95% CI: 33, 81) effective against hospitalizations due to the equine-like G3P[8] genotype. Conclusions These findings are comparable to other countries in the Americas region. To the best of our knowledge, this is the first VE estimate both against the equine-like G3P[8] genotype and from a Caribbean country. Overall, these results support rotavirus vaccine use and demonstrate the importance of complete vaccination.
- Published
- 2021